Wedbush Issues Positive Outlook for Arvinas Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Arvinas in a report issued on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.76) per share for the quarter, up from their previous estimate of ($0.93). Wedbush has a “Neutral” rating and a $12.00 price target on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

ARVN has been the topic of several other reports. BTIG Research assumed coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target on the stock. Stifel Nicolaus dropped their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, February 12th. Citigroup dropped their target price on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, March 7th. Morgan Stanley dropped their target price on Arvinas from $48.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 13th. Finally, Guggenheim dropped their target price on Arvinas from $57.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Arvinas currently has an average rating of “Moderate Buy” and a consensus price target of $37.47.

Arvinas Trading Up 3.2 %

NASDAQ:ARVN opened at $8.70 on Monday. The firm has a market capitalization of $598.32 million, a price-to-earnings ratio of -3.14 and a beta of 1.95. Arvinas has a 1-year low of $7.91 and a 1-year high of $45.03. The business’s fifty day moving average price is $17.09 and its 200 day moving average price is $21.71.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the business earned ($2.53) EPS.

Insider Activity

In related news, insider Ian Taylor sold 9,020 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,572 shares of company stock valued at $695,030. Insiders own 5.23% of the company’s stock.

Institutional Trading of Arvinas

A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. lifted its position in shares of Arvinas by 1.6% in the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock worth $714,000 after acquiring an additional 581 shares during the period. Rhumbline Advisers lifted its position in shares of Arvinas by 0.9% in the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after acquiring an additional 754 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Arvinas by 0.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares during the period. Bank of Montreal Can lifted its position in shares of Arvinas by 2.7% in the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock worth $755,000 after acquiring an additional 1,044 shares during the period. Finally, KBC Group NV lifted its position in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares during the period. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.